Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 5 Date: 26 Apr 2022
Reviewer:  Keita Harada
Reviewer's report:
Thank you for submitting the revised manuscript. The authors sincerely answered our questions
and revised the manuscript. However, it raised new concerns as follows.
Major points
1. The authors clearly stated in the revised version that this study was funded by New Horizon
Health Technology Co. Ltd. Then, althogh the authors declared in page 13 that there was no
potential COI,   there must be some conflict of interest between academia including the authors
and New Horizon Health Technology Co. Ltd. Please disclosure all potential COI.
2. Regarding the previous queri 4 of major points, what do you think was the reason that the
values had not fallen down below the threshould after CRC surgery in the two cases? Figure 6
is not necessary if you consider the residual polyps had nothing to do with the value remaining
positive.
Minor points
1. Please put a registered trade mark on the prodact name ‘ColoClear’, like ColoClear®
Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 5 Date: 26 Apr 2022
Reviewer:  Keita Harada
Reviewer's report:
Thank you for submitting the revised manuscript. The authors sincerely answered our questions
and revised the manuscript. However, it raised new concerns as follows.
Major points
1. The authors clearly stated in the revised version that this study was funded by New Horizon
Health Technology Co. Ltd. Then, althogh the authors declared in page 13 that there was no
potential COI,   there must be some conflict of interest between academia including the authors
and New Horizon Health Technology Co. Ltd. Please disclosure all potential COI.
2. Regarding the previous queri 4 of major points, what do you think was the reason that the
values had not fallen down below the threshould after CRC surgery in the two cases? Figure 6
is not necessary if you consider the residual polyps had nothing to do with the value remaining
positive.
Minor points
1. Please put a registered trade mark on the prodact name ‘ColoClear’, like ColoClear®
Please review this paper.
user
Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 5 Date: 26 Apr 2022
Reviewer:  Keita Harada
Reviewer's report:
Thank you for submitting the revised manuscript. The authors sincerely answered our questions
and revised the manuscript. However, it raised new concerns as follows.
Major points
1. The authors clearly stated in the revised version that this study was funded by New Horizon
Health Technology Co. Ltd. Then, althogh the authors declared in page 13 that there was no
potential COI,   there must be some conflict of interest between academia including the authors
and New Horizon Health Technology Co. Ltd. Please disclosure all potential COI.
2. Regarding the previous queri 4 of major points, what do you think was the reason that the
values had not fallen down below the threshould after CRC surgery in the two cases? Figure 6
is not necessary if you consider the residual polyps had nothing to do with the value remaining
positive.
Minor points
1. Please put a registered trade mark on the prodact name ‘ColoClear’, like ColoClear®
assistant